The systemic oxidative status in hypertensives disorders of pregnancy (HDP) and its association with endothelial dysfunction is controversial. In the present study, we evaluated systemic plasma levels of oxidative stress markers (TBARS (thiobarbituric acidreactive substances) and carbonyl) and total antioxidant status (FRAP (ferric reducing ability of plasma (ferric reducing/antioxidant power) and reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide))), as well as assessed the impact these markers have on nitric oxide (NO) status in healthy pregnant (HP, n ¼ 38), gestational hypertensive (GH, n ¼ 33) and preeclamptic pregnant women (PE, n ¼ 28). We found similar values of TBARS among all groups, and reduced carbonyl levels in HDP between the PE and GH. Conversely, significant increases in plasma activity of antioxidant status were observed in the GH and PE groups compared to the HP group (using both MTT or FRAP method). Importantly, HDP present significantly lower nitrite levels compared to HP women. In Conclusion, our findings show a compensatory antioxidant mechanism against reactive oxygen species (ROS) generation in HDP, which is not associated with nitrite levels restoration.
INTRODUCTION
Preeclampsia, which affects of 3-5% of all pregnancies, is a syndrome of pregnancy characterized by hypertension and proteinuria after 20 weeks of gestation. The development of preeclampsia results in maternal and fetal complications, including renal failure, cerebral edema, liver failure, low birth weight, prematurity and death. 1 Although the pathophysiology of preeclampsia is not completely understood, several lines of evidence point to a failure of cytotrophoblast invasion and absence of dilatation of uterine arteries leading to a highresistance uteroplacental circulation. The decrease in uteroplacental perfusion causes placental hypoxia, which in turn induces the release of factors into the maternal circulation that cause systemic endothelial dysfunction. 2 Some authors suggest that an imbalance between the prooxidantoxidising antioxidant mechanisms may increase the risk of a pregnant women developing hypertensive disorders and endothelial dysfunction. 3, 4 However, whereas some studies have been reported the increased levels of oxidative stress markers 5, 6 and reduced antioxidants in preeclampsia, when compared to healthy pregnant (HP), 7, 8 others show similar values. 9, 10 Importantly, in response to endothelial dysfunction, nitric oxide (NO) is rapidly scavenged by reactive oxygen species (ROS), which reduces its bioavailability. This reduction in NO bioavailability may have an important role in the development of preeclampsia and other hypertensive disorders of pregnancy (HDP). We and others have previously shown that NO markers are reduced during preeclampsia and gestational hypertension (GH), suggesting that decreasing of NO bioavailability is related to HDP. [11] [12] [13] In the present study, we expanded these previous findings and evaluated the systemic plasma levels of oxidative stress markers (thiobarbituric acid-reactive substances (TBARS) 14 and carbonyl 15 ) and total antioxidant status (ferric reducing ability of plasma (FRAP) 16 and reduction of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)) 17 , as well as assessed the impact these markers on NO status in HP, GH and preeclampsia pregnant women (PE).
MATERIALS AND METHODS Subjects
Approval for use of human subjects was obtained from the Institutional Review Board at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil, and informed consent was obtained. A total of 99 pregnant women were enrolled in the Department of Obstetrics and Gynecology, University Hospital of the Faculty of Medicine of Ribeirao Preto. Of these, 38 were HP women with uncomplicated pregnancies, 33 were s GHs and 28 had preeclampsia. Hypertensive disorders were defined in accordance with the guidelines of the NHBPEP (National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy). Gestational hypertension was defined as pregnancy-induced hypertension (X140 mm Hg systolic or X90 mm Hg diastolic on two or more measurements at least 6 h apart) without significant proteinuria in a woman after 20 weeks of gestation, and returning to normal by 12 weeks post partum. Preeclampsia was defined as increased blood pressure with significant proteinuria (X0.3 g per 24 h) in a woman after 20 weeks of gestation. No women with pre-existing hypertension, with or without superimposed preeclampsia, were included in the present study. Exclusion criteria included twin or multiple pregnancies, or any evidence of previous medical illness. No women with pre-existing hypertension, with or without superimposed preeclampsia, or with other comorbidiies (heart diseases, kidney diseases, diabetes, coagulopathies, and so on) were included in the study.
At the time of clinic attendance, maternal venous blood samples were collected into standard Vacutainer tubes (Becton-Dickinson), and immediately the tubes were centrifuged at room temperature and plasma samples were stored at À 70 1C until used to measure the biomarkers.
Assessment of plasma lipid peroxidation and determination of carbonyl content in plasma proteins Lipid peroxidation was assessed by measurement of TBARS, using the method described by Buege and Aust. 14 The determination of carbonyl protein as a general marker of the occurrence of protein oxidation was performed according to the method of Levine et al. 15 The intra-assay coefficients of variation were 5 and 2.53% to TBARS and carbonyl, respectively.
Evaluation of the antioxidant status of plasma
The ferric reducing ability of plasma (ferric reducing/antioxidant power) (FRAP) assay was performed as described previously. 16 In order to measure the direct reduction of MTT (Sigma Chemical Co., St Louis, MO, USA), 100 ml of plasma were mixed with 12.5 ml of dye solution (5.0 mg ml À 1 in PBS); the final volume was adjusted to 200 ml with PBS and the mixture was incubated for 60 min at 37 1C. The reaction was terminated by the addition of 750 ml of 0.04 M hydrochloric acid in isopropanol. The tubes were centrifuged for 10 min at 1000 g, the supernatant collected and the absorbance was measured at 570 nm. The intra-assay coefficients of variation were 2.96 and 2.32% to FRAP and MTT, respectively.
Measurement of plasma nitrite concentrations
Venous blood samples were collected into standard Vacutainer tubes (Becton-Dickinson) containing heparin and immediately centrifuged at 1000 g for 3 min. Plasma aliquots were then immediately removed and stored at À 70 1C until analyzed in triplicate for their nitrite content using an ozone-based chemiluminescence assay, as previously described. 11 Briefly, 200 ml of plasma samples were injected into a solution of acidified triiodide, purging with nitrogen in-line with a gas-phase chemiluminescence NO analyzer (Sievers Model 280 NO Analyzer, General Electric Company, Boulder, CO, USA). Approximately 8 ml of triiodide solution (2.0 g of potassium iodide and 1.3 g of iodine dissolved in 40 ml of water with 140 ml of acetic acid) were placed in the purge vessel into which plasma samples were injected. The triiodide solution reduces nitrite to NO gas, which is detected by the NO analyzer.
Statistical analysis
Data are reported as the mean ± s.d. The clinical characteristics of studied groups were compared by one way analysis of variance followed by the Bonferroni's multiple comparison test. A probability value of o0.05 was considered the minimum level of statistical significance. Table 1 summarizes the clinical characteristics of the 99 subjects enrolled in the present study. We took particular attention in matching the groups based on clinical characteristics that influence oxidative markers, such as: age, gestational age of sampling, ethnicity (all White subjects), smoking and mainly BMI, that is known to alter the levels of these markers. 18, 19 As predicted, PE and GH presented higher systolic and diastolic blood pressure compared with HP (all Po0.05). It should be noted, however, that most hypertensive patients were already receiving antihypertensive therapy at the time of their inclusion in the study. Methyldopa was the preferred drug of choice, but in cases where monotherapy with methyldopa was insufficient to control blood pressure levels, nifedipine was added to the treatment (B20%). Higher proteinuria levels, lower birth weights and gestational ages at delivery were found in the group of preeclamptic women compared with other groups (Po0.05; Table 1 ). As previously demonstrated by our group, 11 plasma nitrite levels were reduced about 50% in hypertensive disorders (Table 1) . Plasma levels of TBARS, protein carbonyl groups (PCG) and antioxidant status of plasma (MTT and FRAP) were evaluated in all groups (Figure 1) . The plasma levels of TBARS were similar in the HP, GH and PE groups (P40.05; 4.6 ± 1.8, 5.0 ± 1.2 and 5.3 ± 1.4 nM, respectively; Figure 1a) . Interestingly, the plasma-PCG levels were significantly reduced in the GH and PE groups when compared to the HP group (Po0.05 for both; 2.3 ± 1.2 and 2.9 ± 2.8 versus 4.9 ± 4.8 nM mg À 1 protein, respectively; Figure 1b) . Conversely, significant increases in plasma activity of antioxidant status of were observed in these groups (GH and PE) compared to HP, using both the MTT (Po0.0001; 0.18 ± 0.01 and 0.19 ± 0.03 versus 0.15±0.03 OD 570 nm, respectively; Figure 1c ) and FRAP (Po0.05; 561±97 and 571±121 versus 496±91 mM, respectively; Figure 1d ).
RESULTS

DISCUSSION
This is the first study to assess concomitantly the plasma levels of nitrite and markers of oxidative stress and antioxidant status in samples of pregnant women, presenting GH, PE and HP. The findings reported here demonstrate similar levels of TBARS and reduced plasma PCG levels in HDP (GH and PE) compared to the HP group. Conversely, higher values of markers of antioxidant status (FRAP and MTT) were found in HDP. Therefore, these data suggest an absence of oxidative stress in HDP. However, despite compensatory mechanisms, lower levels of nitrite were found in HDP, suggesting that rather than the oxidative stress, other pathways may be responsible for the reduction of NO bioavailability found in HDP.
Clinical and experimental studies have shown that an increase in oxidative stress is strongly associated with cardiovascular diseases. 20, 21 The major consequence of increased oxidative stress is a possibility of decreasing NO bioavailability, which is based on knowledge of the fast reaction between NO and superoxide anion (O 2 À ). 22 Indeed, many reports also shown that NO markers are reduced when cardiovascular diseases are present, 11 supporting the idea that oxidative stress is involved in the pathophysiology of cardiovascular diseases by reduction of NO bioavailability. In this regard, whereas a reduction of NO markers during preeclampsia have been consistently demonstrated, 11, 23 the participation of oxidative stress in PE is still controversial, [5] [6] [7] [8] [9] [10] and may be limited by the available methods to assess the biomarkers related. The Oxidative status in hypertensive disorders of pregnancy HF Gomes et al most commonly used method is the determination of the levels of lipid peroxidation products in body fluids, in particular the assessment of TBARS. The absence of significant changes in plasma TBARS levels among groups reported here are consistent, with previous studies showing similar levels of TBARS between PE and HP women. 9, 10 However, other authors have demonstrated higher levels of TBARS in PE compared to HP women. 5, 6 Regarding GH, to our knowledge this is the first study to evaluate these markers in this condition, making a comparison with the literature difficult.
The controversy found in the literature about the TBARS values may be related with the methodology applied, interlaboratory conditions, and mainly by the fact that TBARS not only react with MDA but suffer the interference from other substances present in plasma. 18 For example, the aldehydes other than MDA can affect the final product of reaction between malondialdehyde (MDA) and thiobarbituric acid (TBA) and several other compounds, including sugars, amino acids, and bilirubin are also reactive toward TBA. In addition, MDA does not just reflect lipid peroxidation, but is also a product of cyclooxygenase metabolism in platelets, 24 which is of particular interest when complex samples such as plasma from patients are studied. Supporting the suggestion of lack of increase in the levels of lipid peroxidation markers in PE, some studies measuring the F 2 -isoprostanes levels, a more sensitive marker of oxidative stress, failed to demonstrate the difference between HP and PE. 25 Even though, increases in plasma TBARS have been reported in experimental and clinical studies. This scenario makes clear the necessity to be cautious in interpreting data obtained using only TBARS as an index of oxidative stress. For this reason, we considered other indexes of oxidative stress in the present study, such as markers of the antioxidant status, which has been poorly evaluated in clinical studies, and that could help us to understand the interaction between oxidative stress and hypertensive disorders.
Regarding oxidative damage in proteins, most studies show increased levels in PE. 26 However, Llurba et al. 27 reported a decrease in this parameter in PE, which is consistent with our results. The reduced levels of plasma PCG in PE and GH may be a consequence of the increased antioxidant status in these pregnant women.
Importantly, Llurba et al. 27 demonstrated a significant increase of the major initial reaction products of lipid peroxidation, the total lipid hydroperoxides in PE compared to HP women, although similar results were found regarding MDA levels. This suggests a compensatory and adaptive mechanism, secondary to the increase in free radical's production. Corroborating this idea, our are results demonstrating higher values of the antioxidant status of plasma in PE and GH compared to HP women.
In the current study, we choose the FRAP and MTT methods to evaluate antioxidant parameters instead of individual markers, as these methodologies assess global antioxidant status of plasma. Although several studies have aimed to evaluate antioxidant markers in PE, 6, 8, 27, 28 only one verified the FRAP values, and reported very similar results when compared to our data. 28 This is the first study to evaluate MTT values in PE, and likewise FRAP demonstrated higher antioxidant status in HDP compared to HP women.
A healthy pregnancy is accompanied of a physiologic vascular adaptation including increased blood volume that is accommodated by systemic vasodilatation, where the NO has an important role in the drop of peripheral vascular resistance. 12 Therefore, it is reasonable that a deficiency in the NO may contribute to HDP, such as preeclampsia and gestational hypertension. 13 By the fact that NO is rapidly oxidized, a reliable quantification of its basal production has been relatively challenging. One alternative to study its role is to measure its metabolites, nitrate and nitrite, as index of endogenous NO formation. 29 Regarding nitrate levels, inconsistent results have been reported, studies have demonstrated higher, 30 similar 31 or lower 32 nitrate levels in preeclampsia compared to healthy pregnant women. These discrepancies may be owing to interference of NO synthase independent factors, such as diet, fasting, clinical condition and smoking. On the other hand, it was demonstrated that B70% of plasma nitrite reflect NO synthase activity in the endothelium 33 and that the inhibition of NO synthase activity was associated with corresponding decreases in plasma nitrite concentrations. 33 We observed significant decreases in the nitrite levels in HDP compared to HP women, supporting previous findings 11 and suggesting the participation of NO in pathophysiology of PE and GH. Importantly, although the failure of oxidative damage is observed in our samples, a lack of corresponding restoration of NO availability was found. This finding indicates that other mechanisms independent of oxidative stress may be related to the reduction of NO observed in HDP. These mechanisms may include an increase of NO consumption by cell-free hemoglobin and increased levels of ADMA (asymmetric dimethylarginine), 23, 35 an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), in PE compared to HP women.
In conclusion, our findings show a compensatory antioxidant mechanism against ROS generation in hypertensive disorders of pregnancy (both in PE and GH). Despite this, significant NO reductions are observed in these groups, suggesting that other mechanisms may be involved in the decrease in NO bioavailability. In addition, although important clinical differences were observed between PE and GH women, our data suggest that both are very similar regarding the oxidative status.
What is known about this topic
Nitric Oxide (NO) is rapidly scavenged by ROS. Reduced NO levels are found in hypertensive disorders of pregnancy.
Controversy is found about oxidative status in preeclampsia pregnancy.
What this study adds A compensatory antioxidant mechanism against ROS generation in hypertensive disorders of pregnancy is present. The above mechanism does not restore the NO marker (nitrite) levels in hypertensive pregnant women.
